Epigenetics
How does lactylation-driven ALKBH3 weaken tumor suppressors?
Open access · cc by · source: Europe PMC
Histone lactylation boosts ALKBH3, which removes m1A from SP100A and diminishes PML nuclear condensates, accelerating ocular melanoma progression.
Key findings
ALKBH3 is upregulated in high-risk ocular melanoma with lactylation-linked m1A hypomethylation. Demethylating SP100A impairs PML body formation; ALKBH3 silencing has therapeutic efficacy that SP100A depletion can reverse. YTHDF1 recognizes methylated SP100A transcript.
Methodology
Mapped ALKBH3 upregulation under high histone lactylation, identified SP100A as an ALKBH3 m1A target via multiomics, and tested silencing plus YTHDF1 recognition mechanisms in melanoma models.
Limitations
Does not establish a ready-to-use clinical ALKBH3 inhibitor regimen; ocular melanoma findings may not transfer unchanged to all cancers.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.